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the renin–angiotensin–aldosterone system, and 
cardiomyogenic differentiation of mesenchymal 
stem cells.6 Furthermore, a role in the control of 
food intake and stimulation of gastric, endothe‑
lial, and vascular smooth muscle cell prolifera‑
tion have been reported.7-9
An increase in plasma apelin concentrations in 
human and animal models has been observed in 
patients with metabolic syndrome.10 In this syn‑
drome, apelin has a beneficial effect on the im‑
provement of insulin sensitivity associated with 
an intervention both in glucose and lipid metabo‑
lism. The related antidiabetic and antiobesity roles 
suggest that apelin may be a promising therapeu‑
tic target in metabolic diseases.
Resistin is an adipocyte‑derived hormone that 
has been reported to connect obesity with type 
2 diabetes. Human resistin is a cysteine‑rich pep‑
tide consisting of 108 aminoacids. Its name de‑
rives from the observation that it increases insu‑
lin resistance, although some doubts have been 
raised about the importance of this effect.11 In ad‑
dition to its activity on insulin resistance, resis‑
tin has been also reported to play a potent role 
in inflammation, either directly or through vari‑
ous compounds such as interleukin 6 (IL‑6), tu‑
mor necrosis factor α (TNF‑α), and NF‑κB. In‑
terestingly, IL‑6 and TNF‑α can also regulate re‑
sistin gene expression. In particular, it has been 
observed that TNF‑α strongly increases resistin 
mRNA in human blood mononuclear cells.12 Re‑
sistin has also been reported to reduce the expres‑
sion of endothelial nitric oxide synthase in the en‑
dothelial cells of human coronary arteries and to 
stimulate vascular smooth cell migration, thus 
inducing pathological alteration in the vessels.13
Visfatin is an adipocyte‑derived hormone that 
shows a direct relationship between its plasma 
concentration and type 2 diabetes. Similarly to 
insulin, visfatin causes hypoglycemia. The effect 
depends on its binding to the site of the insu‑
lin receptor, which, although distinct from that 
of insulin, reduces glucose release from the liv‑
er and stimulates glucose utilization by muscle 
Metabolic syndrome comprises a group of factors 
that represent a risk for heart diseases, in par‑
ticular coronary artery disease.1 Atherosclero‑
sis, endothelial dysfunction, hypertension, obe‑
sity, insulin resistance, and diabetes are compo‑
nents of this syndrome, which underlies the high 
incidence of cardiovascular diseases in the indus‑
trialized world. The occurrence of metabolic syn‑
drome is attributed to hormones released by adi‑
pose tissue, which is now also considered an en‑
docrine organ.
In the current issue of the Polish Archives of 
Internal Medicine (Pol Arch Med Wewn), Skoczy‑
las et al2 report a study that investigated the role 
of 3 different adipokines in hypertension and obe‑
sity as well as their response to 4 different types 
of antihypertensive compounds. The referenc‑
es selected by the authors throw some light on 
the significance of the results obtained with ade‑
quate experimental protocols. Owing to the ade‑
quate selection of the references, the introduction 
and discussion sections are a sort of reviews that 
strongly underline the importance of the results.
The study focuses on the changes in plasma 
concentrations of apelin, resistin, and visfatin in‑
duced by antihypertensive treatment in patients 
with hypertension and obesity, compared with 
the changes occurring only in hypertensive non‑
obese or only non‑hypertensive obese subjects.
Apelin is the ligand for the previously orphan 
APJ receptor.3 Although it is a ubiquitous peptide, 
apelin is classified as an adipokine because it is 
produced by adipocytes. Various fragments have 
been isolated as derived from the 77 aminoacid 
preproteins and classified according to the num‑
ber of the aminoacids.3 Out of the various frag‑
ments, apelin‑13 is considered the most active 
form for the cardiovascular system,4 where it ex‑
hibits a positive inotropic effect on the heart and 
a dilatory effect on the vessels, the latter being 
the result of an increased nitric oxide production.
In addition to these basic effects, other im‑
portant activities of apelin have been reported, 
such as protection of the myocardium against 
ischemia–reperfusion injury,5  inhibition of 
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apelin, it cannot be excluded that an antiangioten‑
sin effect may depend on the activation of the an‑
giotensin converting enzyme‑2, which converts 
angiotensin I and angiotensin II into the non‑
vasocontrictor angiotensin 1–7 and angiotensin 
1–9, respectively.
After 6 weeks of treatment, the authors ob‑
served a nonsignificant decrease in plasma ape‑
lin concentrations in nonobese hypertensive pa‑
tients, while an increase was observed in all obese 
hypertensive patients. In these patients, however, 
only the treatment with amlodipine induced a sig‑
nificant increase in apelin plasma levels.
In the discussion section, the authors suggest‑
ed that the decreased apelin plasma level caused 
by indapamide may represent the reason why 
a prolonged hypotensive therapy may become less 
effective with time. This point of view suggests 
that the effectiveness of the antihypertensive 
treatments depend at least in part on the avail‑
ability of apelin.
After 6 weeks of treatment with amlodipine, 
bisoprolol, and indapamide, the authors observed 
a significant reduction of plasma resistin concen‑
trations, while no effect was obtained with can‑
desartan. Bisoprolol reduced also plasma visfa‑
tin concentrations, which was not affected by 
the other compounds.
The differences between the 3 antihyperten‑
sive compounds studied by Skoczylas et al2 can 
be seen in their effect on blood pressure. In fact, 
while apelin is considered to act as a vasodilator 
that contributes to maintaining normal blood 
pressure, resistin has been demonstrated to fa‑
vor the increase of blood pressure in patients 
with metabolic syndrome and to enhance vascu‑
lar responsiveness to other hypertensive com‑
pounds.16 Unlike the other 2 adipokines, visfa‑
tin does not seem to produce any effect on blood 
pressure. These differences must be kept in mind 
when the effects of various antihypertensive 
drugs are studied with regard to the concentra‑
tion and function of endogenous compounds that 
act with different mechanisms in the control of 
blood pressure.
If we refer to the specific compounds exam‑
ined in the present study, we see that also other 
aspects characterize apelin, resistin, and visfatin. 
In fact, the opposite effects on diabetes, shown by 
apelin and visfatin on one side and by resistin on 
the other, are part of broader effects on the syn‑
drome that comprise various metabolic and car‑
diovascular alterations.
In general, when a topic is relatively new and 
still poorly explored, an experimental study must 
give precise answers to some emerging ques‑
tions without confusing the reader. This is what 
Skoczylas et al2 have done successfully in their 
study in that the comparison between the re‑
sponses of different endogenous compounds to 
some selected stimuli represents an important 
step towards a better understanding of these 
compounds.
fibers and adipocytes. Human visfatin consists 
of 401 aminoacids.
An interesting study on visfatin14 showed that 
in heterozygous mice expressing visfatin, glucose 
plasma levels are higher than in wild‑type animals 
in both normal conditions and under glucose tol‑
erance test, indicating a role similar to that of in‑
sulin in lowering plasma glucose concentrations.
From the above description of the activities of 
the 3 different adipokines, it follows that while 
apelin and visfatin can have a beneficial effect 
in diabetes, resistin shows the opposite effect, 
which can also lead to vascular alterations, such 
as atherosclerosis.
As antihypertensive drugs, Skoczylas et al2 
used a β‑blocker (bisoprolol), calcium antago‑
nist (amlodipine), tiazide‑like diuretic (indap‑
amide), and AT1 receptor blocker (candesartan).
The effect of bisoprolol deserves a comment, 
based on the role of body fat in the activity of 
the sympathetic system. It has been suggested 
that aging‑related accumulation of body fat re‑
sults in the chronic stimulation of the sympathet‑
ic system15 via adiposity‑sensitive humoral sig‑
nals, such as leptin and insulin, which can cross 
the blood–brain barrier. The activation of the sym‑
pathetic system should lead to an  increased 
β‑adrenergic thermogenesis aimed at turning into 
heat the energy that otherwise would be stored 
as adipose tissue. Unfortunately, adipogenesis 
replaces thermogenesis when tissue responsive‑
ness is reduced, as it may occur in aged subjects. 
Seals and Bell15 reported that also the reduction 
of β‑adrenergic signaling contributes to the preva‑
lence of adipogenesis with respect to thermogen‑
esis. As a matter of fact, these authors suggest‑
ed that an increase of sympathetic activity, ini‑
tiated by the accumulation of adipose tissue and 
aimed at preventing enhancement of this accu‑
mulation, may paradoxically lead to the develop‑
ment of obesity with aging.
Amlodipine is a dihydropyridine‑type calcium 
antagonist commonly used in the treatment of 
hypertension. Due to the closure of calcium chan‑
nels of vascular smooth muscle cells and cardio‑
myocytes, it is expected not only to produce va‑
sodilatation but also to exert a negative inotro‑
pic effect on the heart. However, since amlodip‑
ine displays its activity more on smooth mus‑
cle cells than on cardiomyocytes, the reduction 
of blood pressure is mainly due to vasodilation 
rather than to reduction of cardiac contractility.
Indapamide is a thiazide‑like diuretic that lim‑
its sodium reabsorption from the renal distal 
convoluted tubule. As a consequence, its antihy‑
pertensive effect is the result of a reduction of 
the fluid circulating volume and not of vasodila‑
tation. Skoczylas et al2 emphasized that the use 
of thiazide diuretics may have a negative effect 
on carbohydrate and lipid metabolism and may 
be responsible for diabetes or lipid disturbances.
Finally, candesartan reduces blood pressure by 
blocking the AI receptors of angiotensin II. Since 
sartans are known to induce the production of 
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